Lopinavir-d8

Lopinavir-d8

• CAS Number: 1224729-35-4
• UNSPSC Description: Lopinavir-d8 (ABT-378-d8) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity[1][2]. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM[3].
• Target Antigen: HIV; HIV Protease; Isotope-Labeled Compounds; SARS-CoV
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Metabolic Enzyme/Protease;Others
• Applications: COVID-19-anti-virus
• Field of Research: Infection
• Solubility: 10 mM in DMSO
• Smiles: CC(C=CC=C1C)=C1OCC(N[C@@H](CC2=CC=CC=C2)[C@@H](O)C[C@H](CC3=CC=CC=C3)NC([C@](N4C(NCCC4)=O)([2H])C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)=O
• Molecular Weight: 636.85
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Cvetkovic RS, et al. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63(8):769-802.|[3]Sham HL, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42(12):3218-3224.|[4]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported